title: Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper.
abstract: It is evident from the data presented above that nausea and vomiting are frequent side effects which are often persistent and distressing to patients. Evidence suggests, and intuitively it appears that avoidance of nausea and vomiting is important to the patients' ability to maintain their quality of life during the treatment period. It is of particular interest to note that in the literature reviewed in this paper standard antiemetic prescribing and practice were followed. It would, therefore, appear that available antiemetic agents are not always effective or may not be adequately employed. The toxicities associated with dopamine receptor antagonists, the current standard of antiemetic regimens, limit their usefulness in the clinical setting. In fact, the contribution of antiemetic therapy toxicities to the incidence of anxiety, fatigue, and restlessness which were commonly reported by patients in the studies reviewed should be considered. Additional effort to characterise the impact of nausea and vomiting on cancer patients' quality of life is needed. Clearly, the data available suggest that these symptoms should be included as part of the physical domain component of quality of life instruments used in cancer patients. Ideally, the instrument used should contain separate items for nausea and vomiting. Major side effects of antiemetic therapy should also be assessed since these may be as debilitating as the effects of nausea and vomiting. Increased awareness of total patient impact of emesis and antiemetic therapy will serve as an impetus for improvements in antiemetic therapy strategies and practices.
authors: School of Medicine, University of North Carolina, Chapel Hill.
authors: C M
authors: CM
authors: Lindley
authors: J D
authors: JD
authors: Hirsch
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000503:physiopathology* / Q000523:psychology*; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014839:Vomiting / Q000139:chemically induced / Q000503:physiopathology* / Q000523:psychology*
chemical_list: D000970:Antineoplastic Agents